News & Topics
News&Topics

2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2021.11.24
SymBio receives approval of shelf-life extension forTREAKISYM ready-to-dilute (RTD) liquid formulation
2021.11.11
Analyst Report[Update report] (Shared Research)
2021.11.11
Summary of Financial Statements for the Third Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
2021.11.11
Notice Concerning Non-operating Expenses
2021.11.11
SymBio Achieves Operating Profit for the Nine Months Ending December 31, 2021 Financial Overview for the Third Quarter of the Fiscal Year
2021.11.11
SymBio announces selection of "Growth Market" as new market segment
2021.11.11
Message from Vice President of SymBio Pharma USA
2021.10.12
SymBio announces commencement of operations of SymBio Pharma USA, Inc.
2021.09.29
SymBio announces presentation of the final results of its Phase 3 Clinical Trial of TREAKISYM in r/r DLBCL at the 83rd Annual Meeting of the Japanese Society of Hematology
2021.09.27
Onconova Therapeutics announces preliminary data on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
2021.09.21
Initiation of controls on shipments of TREAKISYM lyophilized injection formulation
2021.09.09
Analyst Report[Research Coverage Report] (Shared Research)
2021.09.08
SymBio announces initiation of non-clinical study of brincidofovir IV at the Brain Tumor Center, Department of Neurological Surgery University of California, San Francisco
2021.09.01
SymBio enters into a collaborative research agreement with the National Cancer Centre Singapore on Epstein-Barr virus positive lymphoma
2021.08.17
SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of anti-viral drug Brincidofovir IV
2021.08.04
Analyst Report[Update report] (Shared Research)
2021.08.04
Notice Concerning Non-operating Expenses
2021.08.04
Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
2021.08.02
Collaborative research with Kyoto University on mechanism of response of bendamustine for diffuse large B-cell lymphoma
2021.07.15
Notice of Appointment of Corporate Officer
2021.07.15
Collaborative research with Gunma University to explore new indications for bendamustine and rigosertib
2021.06.29
Onconova Therapeutics announces an update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
2021.06.23
Notice of Changes of Director
2021.06.18
Onconova Therapeutics announces the synergistic anti-cancer activity of rigosertib combined with immune checkpoint blockade
2021.06.16
Analyst Report[Full report] (Shared Research)
2021.06.07
Chimerix receives U.S. Food and Drug Administration approval for brincidofovir for the treatment of smallpox
2021.06.01
Analyst Report[Basic Report] (Fair Research)
2021.05.25
New Patent Issued in Japan for Antiviral Agent Brincidofovir
2021.05.21
Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2021.05.19
Chugai receives NHI price listing for polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.05.13
Analyst Report[Update report] (Shared Research)
2021.05.13
Notice of Appointment of Corporate Officer
2021.05.13
Summary of Financial Statements for the First Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
2021.05.10
SymBio submits a partial change application for use of TREAKISYM Liquid Formulation for Rapid Infusion (RI) administration
2021.04.28
SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.04.28
SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.04.26
U.S. Food and Drug Administration granted fast track designation to antiviral agent brincidofovir IV for the treatment of adenovirus infection in pediatric patients
2021.04.26
Onconova Therapeutics announces first patient dosed in an investigator-initiated Phase 2 study of rigosertib in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma
2021.04.23
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2021.04.23
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2021.03.29
SymBio submits partial change application to extend the shelf life of TREAKISYM Ready-To-Dilute (RTD) Formulation
2021.03.25
Notice of Shareholder Voting Results for the16th Ordinary General Meeting of Shareholders
2021.03.25
SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.03.25
SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.03.24
Notice of Appointments to the Board of Directors and the Audit & Supervisory Board, and Appointments of Corporate Officers
2021.03.24
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2021.03.24
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2021.03.23
SymBio receives approval for use of TREAKISYM in combination with rituximab and polatuzumab vedotin as treatment for relapsed or refractory diffuse large B-cell lymphoma
2021.03.23
SymBio receives approval for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
2021.03.11
SymBio submits IND Application for Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV for treatment of Pediatric Adenovirus Infection
2021.03.03
Information on Shareholders' Meeting: Updated the Page
2021.02.26
Chimerix Announces FDA Extends PDUFA Date of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox to July 7, 2021
2021.02.25
Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
2021.02.22
Results of Phase III Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2021.02.04
Analyst Report[Update report] (Shared Research)
2021.02.04
3 Year Mid-Range Plan: FY 2021 to FY 2023
2021.02.04
Notice Concerning Non-Operating Income
2021.02.04
Summary of Financial Statements for the Fiscal Year Ended December 31, 2020 [Japanese GAAP] (Non-consolidated)
2021.01.28
Collaborative research with the Institute of Medical Science, the University of Tokyo, to explore new indications for bendamustine and rigosertib
2021.01.12
Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation